Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology

Future Oncology
Ramez N Eskander, Krishnansu S Tewari

Abstract

Historically, patients with metastatic, persistent or recurrent cervical cancer had limited therapeutic options. Despite several Phase II/III clinical trials, the combination of cisplatin and paclitaxel remained the most effective chemotherapeutic regimen. In 2014, publication of Gynecologic Oncology Group 240 represented the emergence of an alternate and effective therapeutic option. This prospective, randomized, Phase III clinical trial explored the impact of adding the antiangiogenic agent bevacizumab to two separate cytotoxic chemotherapy backbones. Importantly, the study met its primary end point, showing a survival advantage of approximately 4 months without detriment in quality of life. As such, a review of bevacizumab and its application in patients with advanced-stage cervical cancer is warranted.

References

Oct 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P McGuireW T Creasman
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P McGuireG Photopulos
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G A OmuraB Anderson
Apr 4, 1998·The New England Journal of Medicine·A P KudelkaE Loyer
Oct 24, 2000·Obstetrics and Gynecology·W F ChengC Y Hsieh
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P CurtinR D Alvarez
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey D BlossJo Benda
May 12, 2004·Nature Reviews. Drug Discovery·Napoleone FerraraWilliam Novotny
Jun 4, 2004·The New England Journal of Medicine·Herbert HurwitzFairooz Kabbinavar
Jul 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H MooreThomas F Rocereto
May 25, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry J LongUNKNOWN Gynecologic Oncology Group Study
Sep 21, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Tomomi KambaDonald M McDonald
Oct 14, 2005·Current Oncology Reports·Krishnansu S Tewari, Bradley J Monk
Nov 23, 2005·Oncology·Napoleone Ferrara
Dec 16, 2005·Nature·Napoleone Ferrara, Robert S Kerbel
May 2, 2006·Gynecologic Oncology·Jason D WrightJanet S Rader
May 10, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A L Silva-FilhoJ R Cunha-Melo
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Mar 16, 2007·Annals of Surgical Oncology·Muhammad Wasif SaifRonald R Salem
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200
Sep 1, 2007·American Journal of Clinical Oncology·Agustin A GarciaUNKNOWN Gynecologic Oncology Group Study
Dec 28, 2007·The New England Journal of Medicine·Kathy MillerNancy E Davidson
Jan 22, 2008·Cancer Chemotherapy and Pharmacology·Jian-Feng LuJacques Gaudreault
Dec 31, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teri N KreislHoward A Fine
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkLynda D Roman
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bradley J MonkDavid Cella
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry S FriedmanTimothy Cloughesy
Nov 12, 2009·Journal of the National Cancer Institute·Kristine R Broglio, Donald A Berry
Jan 9, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Diane R Mould, Bruce Green
Jul 9, 2010·Clinical Pharmacokinetics·Ron J KeizerJos H Beijnen
Dec 15, 2010·Journal of the National Comprehensive Cancer Network : JNCCN·Benjamin E GreerUNKNOWN National Comprehensive Cancer Networks
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Apr 30, 2011·The New England Journal of Medicine·UNKNOWN CATT Research GroupGlenn J Jaffe
Dec 30, 2011·The New England Journal of Medicine·Robert A BurgerUNKNOWN Gynecologic Oncology Group

❮ Previous
Next ❯

Citations

Jan 17, 2015·Clinical Therapeutics·Ramez N Eskander, Krishnansu S Tewari
Mar 31, 2016·The Oncologist·Jill K Alldredge, Krishnansu S Tewari
Sep 21, 2018·American Society of Clinical Oncology Educational Book·Ramez N Eskander
May 15, 2021·Human Vaccines & Immunotherapeutics·Sylvia Annabel DassVenugopal Balakrishnan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.